|
Your Cart is Empty
|
| Good News for Women and Their Breast Health |
|
|
|
Research suggests that our bodies use natural plant lignans, now sparse in the the modern diet, to safely and gently buffer and balance potentially adverse effects of excess or toxic estrogens, established as the most well-known cause of certain breast problems. Studies in animals with breast cancer have found that lignans from whole flaxseed and pure lignan:
High Lignan Product Now Availablelignan SDG. The safety and tolerability of SDG from flax seed meal has been assessed in numerous clinical trials—in all of these no significant adverse effects have been observed.
A dramatic 300% reduction in breast cancer risk has been noted in women consuming a high intake of lignan as compared to women whose consumption of lignan was relatively low. This is a significant breakthrough for women today, as you will see as you read on.
Sobering Facts About Breast Cancer The number of women that can fill a baseball stadium holding 46,000 baseball fans-that number of women from young adults to seniors, women of all professions and all races—46,000, will die this year from breast cancer. More than 211,000 will be diagnosed in this year (2003) with breast cancer. More than 2 million breast cancer survivors live in the US today. 90% of those diagnosed with breast cancer have had no family history of the disease.
Beginning in the year 2000, the American Cancer society's annual projections indicate an alarmingly sharp increase in breast cancers. Estrogen Window All women are exposed to estrogen but research shows that those women exposed to higher amounts of estrogen over a lifetime have a higher incidence of a breast cancer diagnosis—this is called the estrogen window. The estrogen window opens wider with each increase in exposure. Factors which increase exposure are:
Closing the Estrogen Window The following lifestyle factors can "close" the estrogen window, that is—can decrease overall exposure to estrogen.
Block the Effects of Excessive Estrogen Currently available medical therapies focus on drugs that reduce the growth promoting effects of estrogens on breast and uterine cells. Tamoxifen is one of the most widely used anti-cancer agents. However, adverse events have been associated with the use of Tamoxifen including an elevated risk for endometrial cancer, and increased incidence of cardiovascular disease.
Women need a safe, effective and well tolerated substance that can reduce exposure to estrogen. A recent study conducted among women in eastern Finland (where dietary lignan intake is typically higher than in the U.S.) found that in 194 pre and post menopausal women, higher blood lignan concentrations were linked to a striking reduction in breast cancer risk. The highest phytoestrogen consumption and concentrations in biological fluids are found in women living in countries where cancer incidence is low, while the lowest concentrations were found in breast cancer patients or in women at high risk for breast cancer. These findings led researchers to assess the effects of flax. An abundance of animal and human research suggests that the flaxseed lignan exerts effects similar to the anti-estrogen drug tamoxifen with apparently a much greater degree of tolerability. Concentrated Lignan, A Natural Product from Brevail Since phyto estrogens are found in only trace amounts in grains, vegetables, and fruits, it's hard to acheive a lignan rich diet. Brevail's breakthrough technology enables an effective daily amount of natural plant lignans to be delivered in a one-a-day capsule dose.
In a three month trial usage program, women who increased their SDG lignan intake experienced greater peace of mind and well-being. PMS, peri, pre and post menopausal symptoms improved. SDG lignans cannot fully saturate receptor sites or replace estrogen so the natual balance is maintained. If you are taking HRT, tamoxifan or any other treatment check with your physician. Information has not been evaluated by the Food and Drug Administration. Not intended to cure, diagnose, treat, cure or prevent any disease. Educational purposes only, not intended to replace or contradict any health care professional. BREVAIL, WINNER OF TWO CONSECUTIVE RESEARCH GRANTS Brevail was awarded an unprecedented two consecutive research grants by the Washington Technology Center, University of Washington, in the course of the 6-year span in which it was developed. Lignan Based Strategies for Cancer Prevention was the topic and title of the grants.
BREVAIL, SUBJECT OF HUMAN, ORAL-DOSING STUDIES Brevail was the subject of two, human, university based, pharmacokinetic studies designed to determine its optimal oral dose in women. The studies were successful in attaining lignan levels in the participants comparable to a reference group of women who exhibit an extraodinary history of breast helath, revealing the ideal human oral dose for Brevail in adult females.
BREVAIL, TESTED FOR SAFETY Brevail was the subject of acute oral toxicity testing, in which absolutely no toxicity was found.
|
| < Prev | Next > |
|---|
Articles
WOMEN'S HEALTH
Good News for Women and Their Breast Health Statements on this page have not been evaluated by the Food & Drug Administration and are not intended to diagnose or treat disease.